Moberg Pharma’s nomination committee appointed

In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 13.

Moberg Pharma’s Nomination Committee ahead of the 2015 Annual General Meeting comprises: 

• Mats Petterson, Chairman of the Board
• Per-Olof Edin, appointed by Östersjöstiftelsen
• George E. Aitken-Davies, appointed by Altaris Capital Partners (JPM Chase NA)
• Ulrica Slåne Sens, appointed by Tredje AP-fonden

Per-Olof Edin has been appointed Chairman of the Nomination Committee. Together, the Nomination Committee represents 26.7 percent of the shares in Moberg Pharma as of September 30, 2014.

The Nomination Committee shall submit proposals for resolution by the 2015 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

The 2015 Annual General Meeting will be held in Stockholm on May 11.

Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to [email protected] by 31 December 2014.